Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meridica Ltd.

Division of Pfizer Inc.
www.meridica.com

Latest From Meridica Ltd.

Aegate Ltd.

Unlike track and trace systems that focus on the drug supply chain leading up to the pharmacist's back door, Aegate Ltd. is concerned about what takes place at the end of the process-the point of dispensing to the patient. Its technology is designed to identify fraudulent products and to reduce dispensing errors on the part of pharmacists.

Pfizer's Analyst Day: And Now, For Its Next Trick

Pfizer was vague in describing to analysts just how it would reduce costs by $4 billion per year by 2008. The FDA's announcement that it had asked Pfizer to remove the Cox-2 inhibitor Bextra from the market just days later complicates matters for the pharmaceutical giant. In any case, those hoping for a significant headcount reduction among Pfizer sales reps were surely disappointed.
BioPharmaceutical Strategy

Idun the Latest to Seek Shelter via Pfizer's M&A Highway

In February, Idun Pharmaceuticals became the fourth company acquired by Pfizer in the last 15 months. While those transactions reflect different mixes of product and technology breadth, they suggest a greater alignment between the interests of some private biotechs, their investors, and potential pharma company acquirers, as well as an evolution in the deal calculus for choosing M&A over an alliance or IPO.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Nasal
      • Pulmonary
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Ian Smith, PhD, CEO
    Martin J Smith, Dir., Fin
    David Edwards, Dir., Mktg.
  • Contact Info
  • Meridica Ltd.
    Phone: (44) 1763 261 600
    Cambridge Technology Ctr.
    Melbourn, Royston, SG8 6DQ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register